Prostate Cancer Clinical Trial
68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
Summary
The purpose of this study is to see if a new diagnostic research agent named 68Ga-RM2 can show prostate cancer on a PET/CT scan. 68Ga-RM2 stands for Galium-68 labeled DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2. This study is being done because there are unmet medical needs to improve the current ways of detecting prostate cancers before surgery.
Eligibility Criteria
Inclusion Criteria:
Age ≥18 years
Biopsy proven adenocarcinoma of the prostate
Patients with low-risk, intermediate-risk and high-risk tumors according to NCCN guidelines (2.2014) will be included
Planned radical prostatectomy at MSKCC
Multiparametric MRI of the pelvis (performed or planned) as routine care
Exclusion Criteria:
Patients meeting any of the following exclusion criteria will not be eligible for study entry:
Hematologic
Platelets <75K/mcL
ANC <1.0 K/mcL
Hepatic laboratory values
Bilirubin >2.0 x ULN (institutional upper limits of normal)
AST/ALT >2.5 x ULN
Renal laboratory values
o Creatinine > 2.0 x ULN
Claustrophobia interfering with MRI and PET/CT imaging
Prior pelvic radiation
Prior androgen deprivation therapy
Patients deemed not surgical candidates due to prohibitive co-morbidities
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.